Supplemental Grant Application Instructions II-2 . Scenario C. Exempt Human Subjects Research If all of the proposed human subjects research meets the criteria for one or more of the exemptions from the requirements in the HHS regulations (46.101(b)) (see Part III Section 3 under Human Subjects Research
Adults with one of the above listed conditions who have not received any pneumococcal vaccine should get a dose of PCV13 first and should also continue to receive the recommended doses of PPSV23. Ask your health care provider for details.
Indications for Prevnar 13 1  Â®. Prevnar 13 Â® is a vaccine approved for adults 50 years of age and older for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). In children 6 weeks through 5 years of age (prior to the 6th birthday) Prevnar 13 Â® is indicated for the prevention of otitis media caused by S pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.